February 2024 in “Journal of the European Academy of Dermatology and Venereology” In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.
August 2023 in “Dermatology and Therapy” This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.
1 citations
,
June 2023 in “Genes” This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
5 citations
,
August 2022 in “Psychology Research and Behavior Management” This study found that nearly half of those perceiving hair loss reported a significant impact on their quality of life, highlighting potential benefits of seeking medical advice for diagnosis and treatment.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.
1 citations
,
January 2021 in “Skin appendage disorders” This study observed that alopecia areata in children often presents as mild scalp patches, with the majority showing some hair regrowth following treatment, particularly when using potent topical steroids, which were most commonly prescribed in the reviewed cases.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.
13 citations
,
April 2020 in “Dermatology and therapy” This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
11 citations
,
January 2020 in “Dermatologica Sinica” This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.
15 citations
,
December 2019 in “European Journal of Dermatology” This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.
17 citations
,
August 2018 in “Journal der Deutschen Dermatologischen Gesellschaft” This study found that dissecting folliculitis is more common than previously thought in Taiwan, with obesity possibly linked to higher severity of this condition, but smoking not associated.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
8 citations
,
July 2018 in “The Journal of Dermatology” In this retrospective study, researchers observed that additional rounds of intravenous corticosteroid pulse therapy led to only partial hair regrowth in some rapidly progressive alopecia areata cases, with all participants experiencing relapse, indicating limited efficacy for severe cases resistant to initial treatment.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.
15 citations
,
March 2018 in “Cancer Medicine” This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.
89 citations
,
March 2018 in “The Journal of Dermatology” This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.
28 citations
,
December 2017 in “Lasers in Medical Science” This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.
63 citations
,
January 2017 in “Annals of Dermatology” More research is needed to understand alopecia areata severity.
16 citations
,
November 2016 in “Journal of Cosmetic and Laser Therapy” This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.
25 citations
,
June 2015 in “Scientific Reports” In this study, patients with alopecia areata were found to have a higher risk of stroke over a 3-year follow-up period compared to those without the condition.
4 citations
,
December 2014 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
19 citations
,
January 2013 in “Annals of Dermatology” In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.
26 citations
,
September 2012 in “Journal of The American Academy of Dermatology” This study observed that patients with rapidly progressive alopecia areata may have a favorable prognosis regardless of treatment, and regenerated vellus hairs were linked to higher improvement or cure rates.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
21 citations
,
February 2012 in “Journal of the European Academy of Dermatology and Venereology” This study found that late-onset alopecia areata is more common in women and tends to present with milder symptoms, with some patients achieving complete hair regrowth in mild cases.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.
64 citations
,
November 2008 in “Journal of The American Academy of Dermatology” This study observed that acute diffuse and total alopecia, a subtype of alopecia areata, typically resolves rapidly and spontaneously within about six months, even without treatment, suggesting a favorable prognosis.
275 citations
,
November 2002 in “International Journal of Dermatology” This study found that among an Asian population with alopecia areata, commonly first episodes occurred before age 40, with severe cases linked to psychological effects and treatments showing significant regrowth.
59 citations
,
January 2002 in “Dermatology” This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.
